A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002195
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
- Detailed Description
This is a double-blind, placebo-controlled, two-arm study comparing treatment with a triple regimen consisting of 141W94, retrovir, and epivir and a double regimen consisting of retrovir and epivir.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 290
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
Chicago Ctr for Clinical Research
🇺🇸Chicago, Illinois, United States
Dr Bruce Rashbaum
🇺🇸Washington, District of Columbia, United States
Community Research Initiative of South Florida
🇺🇸Coral Gables, Florida, United States
Community Research Initiative of Central Florida
🇺🇸Maitland, Florida, United States
Saint Vincent's AIDS Ctr
🇺🇸New York, New York, United States
Pacific Oaks Research
🇺🇸Beverly Hills, California, United States
Univ of Miami School of Medicine
🇺🇸Miami, Florida, United States
Methodist Hosp
🇺🇸Memphis, Tennessee, United States
Community Research Initiative of New England
🇺🇸Brookline, Massachusetts, United States